Clinical Trial Update: A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing LY900003 plus gemcitabine and cisplatin to gemcitabine and cisplatin in patients with advanced, untreated non-small cell lung cancer has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemzar (gemcitabine)
• LY900003

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED